 BRIDGEWATER, N.J.--BUSINESS WIRE--Amneal Pharmaceuticals, Inc. NYSE: AMRX Amneal or the Company today announced that it has received Abbreviated New Drug Application ANDA approval from the U.S. Food and Drug Administration FDA for 150 mcgday Norelgestromin and 35 mcgday Ethinyl Estradiol Transdermal System. In conjunction with its approval, Amneal received a Competitive Generic Therapy CGT designation by the FDA and has been granted 180 days of exclusivity. Amneals Norelgestr 